Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6-grass pollen mixture is a biologic allergen immunotherapy developed by ALK-Abello for the treatment of grass pollen-induced allergic rhinitis. The product is a standardized allergenic extract formulated as an injection solution (and also investigated for sublingual use) containing a specific blend of pollens from six grass species: *Agrostis gigantea* (Redtop), *Dactylis glomerata* (Orchard grass), *Festuca pratensis* (Meadow Fescue), *Lolium perenne* (Perennial Rye), *Phleum pratense* (Timothy), and *Poa pratensis* (Kentucky Blue grass). It is typically available in multiple-dose vials at a concentration of 100,000 BAU/mL (Bioequivalent Allergy Units per milliliter). The therapy works by desensitizing the patient's immune system through regular exposure to the allergens, eventually leading to clinical tolerance and a reduction in symptoms and the need for rescue medication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-grass pollen mixture.